Multiple Myeloma is a cancer of the blood that begins in plasma cells, which are a vital part of the immune system. When healthy plasma cells in bone marrow acquire mutations, they can turn into cancerous cells. When these cancerous cells grow uncontrollably, they overcome healthy blood cells, decimating bone tissue and spreading cancer throughout the body. The disease leads…
Read More
New funding: Seattle biotech startup Oisín Biotechnologies has raised a $5 million seed round. It’s currently developing preclinical therapies that target and kill damaged cells that have been biologically turned off or are “senescent” and supposed to die. But as people get older, the cells can persist as “zombie cells” that accumulate and are associated with aging-related diseases. The round was led by Althea…
Read More
Seattle Children’s researchers have published a study that has uncovered a deeper understanding of why people who have had mild cases of the novel coronavirus 2019 (COVID-19) lose functional antibodies within a few months. Last year, while seeing the bulk of research analysis focused on severe cases of COVID-19, a team of researchers led by Seattle Children’s Research Institute’s Center for…
Read More
Dr. Ruanne Barnabas, associate professor (Allergy and Infectious Diseases), has been awarded the 2021 Minority Faculty Mentoring Award by the UW School of Medicine Committee on Minority Faculty Advancement (CMFA). This award recognizes the need for excellence in mentoring of under-represented faculty groups to achieve diversity and inclusion, key elements that can unleash creativity and innovation so that we can meet the health…
Read More
In response to the technological advances of recent years, the International Society for Stem Cell Research today (May 26) released an updated version of its guidelines for basic and clinical research involving human stem cells and embryos. The ISSCR’s changes include recommendations for using human embryo models, lab-derived gametes, and human-animal chimeras as well as an end to the widely…
Read More
Prostate cancer (PC) is driven by androgen receptor (AR) activity, a master regulator of prostate development and homeostasis. Frontline therapies for metastatic PC deprive the AR of the activating ligands testosterone (T) and dihydrotestosterone (DHT) by limiting their biosynthesis or blocking AR binding. Notably, AR signaling is dichotomous, inducing growth at lower activity levels, while suppressing growth at higher levels.…
Read More
After Sana Biotechnology raised a whopping $587 million in its initial public offering, the company aims to hire an additional 100 people to staff its sites in Seattle, San Francisco, and Cambridge, Mass. by the end of the year. In an interview with the Puget Sound Business Journal, Sana Chief Executive Officer Steve Harr said the company is poised for significant growth as the cell…
Read More
A COVID-19 nanoparticle vaccine candidate, named GPB510, has received significant additional funding from the Coalition for Epidemic Preparedness Innovations (CEPI). The funding, which will go to SK bioscience, will enable multi-national Phase 3 clinical trials, and also support additional research and development on emerging coronavirus variants of concern. It will also fund further scale-up of SK bioscience manufacturing to full commercial scale,…
Read More
New funding: Eliem Therapeutics raised $60 million to further development of its therapies for pain and depression. The fresh funding comes just two months after Eliem raised a $80 million round. The pipeline: Founded in 2019, the company has two lead drug candidates in development: ETX-810 for chronic pain and ETX-155 for major depressive disorder, hormone-related mood disorders, and focal onset seizures. Both are…
Read More